Centerpoint Advisors, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.

Quarter-by-quarter ownership
Centerpoint Advisors, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$27
+8.0%
7000.0%0.01%
+10.0%
Q2 2023$25
-7.4%
7000.0%0.01%
-16.7%
Q1 2023$27
-32.5%
7000.0%0.01%
-36.8%
Q4 2022$40
-99.9%
700
-33.3%
0.02%
-13.6%
Q3 2022$42,000
-8.7%
1,0500.0%0.02%
-4.3%
Q2 2022$46,000
+9.5%
1,0500.0%0.02%
+21.1%
Q1 2022$42,000
-4.5%
1,050
-4.5%
0.02%0.0%
Q4 2021$44,000
-2.2%
1,1000.0%0.02%
-9.5%
Q3 2021$45,000
-10.0%
1,1000.0%0.02%
-12.5%
Q2 2021$50,000
+8.7%
1,1000.0%0.02%
-11.1%
Q1 2021$46,000
-2.1%
1,1000.0%0.03%
-12.9%
Q4 2020$47,000
+62.1%
1,1000.0%0.03%
+40.9%
Q3 2020$29,0000.0%1,1000.0%0.02%
-4.3%
Q2 2020$29,000
+45.0%
1,1000.0%0.02%
+15.0%
Q1 2020$20,0000.0%1,1000.0%0.02%
+33.3%
Q4 2019$20,000
+17.6%
1,1000.0%0.02%
+7.1%
Q3 2019$17,000
-10.5%
1,1000.0%0.01%
-6.7%
Q2 2019$19,000
+5.6%
1,1000.0%0.02%0.0%
Q1 2019$18,000
+12.5%
1,1000.0%0.02%0.0%
Q4 2018$16,000
-20.0%
1,1000.0%0.02%
-6.2%
Q3 2018$20,000
+5.3%
1,1000.0%0.02%0.0%
Q2 2018$19,000
-13.6%
1,1000.0%0.02%
-15.8%
Q1 2018$22,0000.0%1,1000.0%0.02%0.0%
Q4 2017$22,0001,1000.02%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$51,293,0007.24%
First Light Asset Management, LLC 2,050,273$93,103,0005.59%
TRAN CAPITAL MANAGEMENT, L.P. 1,350,870$61,343,0005.06%
SNYDER CAPITAL MANAGEMENT L P 3,176,404$144,241,0004.04%
DOHENY ASSET MANAGEMENT /CA 91,930$4,175,0002.69%
Redwood Investments, LLC 538,656$24,460,0001.97%
HighMark Wealth Management LLC 53,457$2,427,0001.78%
Taylor Wealth Management Partners 85,409$3,878,0001.37%
SILVERARC CAPITAL MANAGEMENT, LLC 66,673$3,028,0001.35%
Granite Investment Partners, LLC 919,029$41,733,0001.29%
View complete list of HALOZYME THERAPEUTICS INC shareholders